| Diabetes Mellitus, Non-Insulin-Dependent
Kombiglyze XR vs Trijardy XR
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Kombiglyze vs Trijardy Xr with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTrijardy Xr has a higher rate of injection site reactions vs Kombiglyze based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trijardy Xr but not Kombiglyze, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kombiglyze
Trijardy Xr
At A Glance
Oral
Once daily
DPP4 inhibitor + biguanide
Oral
Daily
SGLT2i / DPP-4i / biguanide
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Administer once daily with the evening meal; individualize starting dose based on current regimen; max 5 mg saxagliptin/2,000 mg metformin HCl extended-release once daily; limit saxagliptin to 2.5 mg daily with strong CYP3A4/5 inhibitors; swallow tablets whole.
Diabetes Mellitus, Non-Insulin-Dependent Individualize starting dose based on current regimen; maximum 25 mg empagliflozin / 5 mg linagliptin / 2,000 mg metformin HCl once daily; take orally once daily with morning meal, swallow whole. Not recommended for initiation if eGFR <45 mL/min/1.73 m2; contraindicated if eGFR <30 mL/min/1.73 m2.
Contraindications
- Severe renal impairment (eGFR below 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- History of serious hypersensitivity reaction to saxagliptin, metformin HCl, or any ingredient in KOMBIGLYZE XR, including anaphylaxis, angioedema, or exfoliative skin conditions
- Severe renal impairment (eGFR less than 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Hypersensitivity to empagliflozin, linagliptin, metformin HCl, or any excipient (anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred)
Adverse Reactions
Most common (>=5%) Upper respiratory tract infection, urinary tract infection, headache (saxagliptin); diarrhea, nausea/vomiting (metformin)
Serious Lactic acidosis, pancreatitis, heart failure, hypoglycemia with insulin or insulin secretagogues, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid, vitamin B12 decrease
Postmarketing Pancreatitis, anaphylaxis, angioedema, exfoliative skin conditions, rhabdomyolysis, bullous pemphigoid, cholestatic and hepatocellular liver injury
Most common (>=5%) Upper respiratory tract infection, urinary tract infection, nasopharyngitis, diarrhea, constipation, headache, gastroenteritis
Serious Lactic acidosis, diabetic ketoacidosis, pancreatitis, volume depletion, genitourinary infections (urosepsis, pyelonephritis, Fournier's gangrene, genital mycotic infections), hypoglycemia with insulin or insulin secretagogues, lower limb amputation, hypersensitivity reactions, vitamin B12 deficiency, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis (including fatal), mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, rhabdomyolysis, acute kidney injury, bullous pemphigoid, rash, urticaria, cholestatic and hepatocellular liver injury
Pharmacology
Kombiglyze XR combines saxagliptin, a competitive DPP4 inhibitor that slows incretin hormone (GLP-1, GIP) inactivation to enhance glucose-dependent insulin release and suppress glucagon, and metformin HCl, a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity.
TRIJARDY XR combines three complementary mechanisms: empagliflozin (SGLT2 inhibitor) reduces renal glucose reabsorption and increases urinary glucose excretion; linagliptin (DPP-4 inhibitor) increases active incretin hormones (GLP-1, GIP) to stimulate glucose-dependent insulin release and reduce glucagon; and metformin HCl (biguanide) decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kombiglyze
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Trijardy Xr
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (5/12) · Qty limit (11/12)
UnitedHealthcare
Kombiglyze
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Trijardy Xr
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Kombiglyze
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Trijardy Xr
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Kombiglyze.
No savings programs available for Trijardy Xr.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KombiglyzeView full Kombiglyze profile
Trijardy XrView full Trijardy Xr profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.